We describe a man with allogeneic BMT who developed Dipodascus capitatus (anamorph Geotrichum capitatum) spondylodiscitis. Relapse of the bone and joint lesions remained culture negative and paralleled the immune restitution, suggesting an immune reconstitution inflammatory syndrome (IRIS).
A 48-year-old patient was diagnosed with AML. During induction chemotherapy (daunorubicin, cytarabine and etoposide) and consolidation cycle he received antifungal prophylaxis with oral posaconazole (200 mg/8 h). In May 2008, he underwent allogeneic related HLA-matched BMT after myeloablative conditioning with BU and CY. GVHD prophylaxis with CYA was adjusted to the 250 ng/ml blood level. On day 2 of neutropenia, he developed fever and grade IV mucositis. Four blood cultures yielded D. capitatus. Fungemia was cured with a 14-day course of liposomal Amphotericin B (L-AmB) (3 mg/kg per day). Leukemia CR was confirmed and CYA was gradually tapered. At 3 months after BMT, the patient complained of low back and right hip pain along with S1 radiculalgia. Magnetic resonance imaging (MRI) showed L5-S1 spondylodiscitis with destructions of the vertebral end plates and the disc, vertebral anterior abscess and epidural inflammation (Figures 1a and b) . A L5-S1 bone sample obtained through fine needle aspiration grew D. capitatus. He was started on oral voriconazole (standard dose). After 2 weeks, he developed cough, dyspnea and fever. The chest CT scan showed ground glass opacities and micronodules spreading over both lungs. The bronchoalveolar lavage (BAL) fluid yielded only D. capitatus. Identification of one blood, the bone and the BAL isolates was confirmed by molecular methods (ITS sequencing).
1 Serum galactomannan (Platelia Aspergillus; Bio-Rad, Marnes-la-Coquette, France), screened twice weekly, tested persistently negative. Voriconazole trough blood levels were monitored weekly and showed constant results above 1 mg/L. A repeat MRI revealed a probable L3 anterosuperior spondylitis that had not been detected on the first imaging. Concern about progression of the vertebral infection and probable pulmonary involvement led to switch to L-AmB therapy Voriconazole trough levels were confirmed to be satisfactory. A relapse of the fungal infection was initially suspected and the combination of posaconazole (200 mg/6 h) and oral 5-flucytosine (2500 mg/8 h) was prescribed. After 1 month, the patient's condition improved. After a 3-week period free of antifungal therapy, during which no recurrence occurred, a bone sample and blood from the surrounding soft tissues were collected from the L4-L5 lesions. No pathogen grew and a panfungal PCR targeting the ITS did not detect any fungal DNA in those two specimens. Histological analysis of the inferior end plate of L4 showed unspecific chronic osteitis with inflammatory cells (lymphocytes and plasmocytes) within areas of fibrosis. Over the next 6 months, the patient remained stable and MRI performed in May 2010 confirmed the improvement as both the edema and the epiduritis resolved. Only the hypersignal observed on the L2-L3 end plates endured.
D. capitatus (anamorph G. capitatum) is a filamentous yeast-like fungus that composes a part of the normal human flora of the skin, the gastrointestinal and respiratory tracts. 1 Infections in immunocompromised patients often mimic invasive candidiasis but are more likely associated with multiorgan involvement and fatal course.
2,3 Here, we report a case of disseminated D. capitatus infection with spondylodiscitis and probable pneumonia in a patient with allogeneic BMT. Only two other patients with D. capitatus spondylodiscitis have been described. 4, 5 Our patient experienced significant improvement of the L5-S1 bone and disc infections after prolonged L-AmB therapy and the subsequent deterioration observed after 3 months of voriconazole was unexpected. First, the drug blood levels, which were repeatedly measured, were persistently above 1 mg/L, a threshold that has been linked to appropriate absorption and therapeutic success. 6 These drug levels were satisfactory regarding the minimal inhibitory concentration (MIC) values exhibited by the isolates (voriconazole MICs ranged from 0.125 to 0.25 mg/L). However, it must be stressed that no interpretative criteria for the in vitro tests have been proposed for this fungus. Second, the patient experienced, concurrent with the relapse, a decrease (even more a discontinuation of corticosteroids) of the immunosuppressive therapy and control of the GVHD, two conditions that usually favor the recovery of invasive fungal infections in general, and D. capitatus infections in particular. 2 Third, as voriconazole has shown high ability to penetrate bone and is orally available, it appears a drug of choice in fungal osteomyelitis management. 7 The temporal association of new vertebral lesions that remained culture-negative despite a three-week period free of any antifungal therapy, histological findings showing unspecific osteitis with fibrosis and inflammatory cells, and immune restoration is highly reminiscent of IRIS. This syndrome was initially described in AIDS patients with fungal infections such as cryptococcosis, histoplasmosis and pneumocystosis, and who responded to antiretroviral therapy. 8 IRIS has been also reported in neutropenic patients with exacerbation of invasive aspergillosis and in chronic disseminated candidiasis. 9, 10 In the present case, D. capitatus grew in respiratory samples and was initially recovered as the sole pathogen. Given the concurrent findings of clinical pneumonia and radiological features observed on the chest CT scan, this condition most likely suggests a lower respiratory tract infection due to D. capitatus and we considered it as probable specific pneumonia. From the most comprehensive review, D. capitatus pneumonia was common and accounted for 19% of the invasive infections. 3 The authors suggested, and our case supports this recommendation, that in immunocompromised patients with documented pneumonia, repeated D. capitatus recovery from the respiratory tract without other pathogens should be considered as clinically significant.
In conclusion, although D. capitatus disseminated and spondylodiscitis infections are rare, their management remains difficult. In the present case, we described temporal association of spondylodiscitis deterioration and immune restitution that was highly reminiscent of IRIS, a condition that has been described neither in fungal spondylodiscitis, nor in D. capitatus infections. 
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